U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H23N5O2S
Molecular Weight 457.547
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BENTAMAPIMOD

SMILES

N#CC(C1=NC2=C(S1)C=CC=C2)C3=CC=NC(OCC4=CC=C(CN5CCOCC5)C=C4)=N3

InChI

InChIKey=XCPPIJCBCWUBNT-UHFFFAOYSA-N
InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2

HIDE SMILES / InChI

Molecular Formula C25H23N5O2S
Molecular Weight 457.547
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27027242 http://www.pharmacodia.com/yaodu/html/v1/chemicals/a438a122ad7b41a2d652eccda5a6711b.html

Bentamapimod (AS602801) a newly developed, orally-active, ATP competitive inhibitor of JNK, which is in phase IIa clinical trials for the treatment of endometriosis. Bentamapimod showed selective cytotoxic activity against serum-cultured cancer cells and cancer stem cells in vitro. It blocks T-cell proliferation and induces apoptosis. Bentamapimod was discovered by Merck Serono. Then PregLem (a member of the Richter Group) acquired worldwide rights in 2010.

CNS Activity

Curator's Comment: Bentamapimod (AS602801) does cross the blood brain barrier, with 98% brain penetration

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL

Sample Use Guides

320mg/day (160 mg twice a day) for 8 weeks
Route of Administration: Oral
Bentamapimod (AS602801) treatment induced cell death and accordingly decreased the number of viable cells in three cell lines (PANC-1, pancreatic cancer; A594, lung cancer; A2780, ovarian cancer) in a dose-dependent manner (7.5 uM being most effective)
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:58 UTC 2023
Edited
by admin
on Fri Dec 15 16:30:58 UTC 2023
Record UNII
TT3L4B4U0N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENTAMAPIMOD
INN   WHO-DD  
INN  
Official Name English
AS602801
Code English
bentamapimod [INN]
Common Name English
2-(1,3-BENZOTHIAZOL-2-YL)-2-(2-((4-((MORPHOLIN-4-YL)METHYL)PHENYL)METHOXY)PYRIMIDIN-4-YL)ACETONITRILE
Systematic Name English
PGL5001
Code English
AS-602801
Code English
Bentamapimod [WHO-DD]
Common Name English
PGL-5001
Code English
Classification Tree Code System Code
NCI_THESAURUS C2149
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
Code System Code Type Description
FDA UNII
TT3L4B4U0N
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
CAS
848344-36-5
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
INN
8919
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
PUBCHEM
10195250
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
EPA CompTox
DTXSID401005116
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
CHEMBL
CHEMBL3545213
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
SMS_ID
300000036960
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
NCI_THESAURUS
C87441
Created by admin on Fri Dec 15 16:30:58 UTC 2023 , Edited by admin on Fri Dec 15 16:30:58 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
ENANTIOMER -> RACEMATE
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY